강병주 교수

논문

• 1. Ghang BZ, Lee JW, Kim JH, Seo YR, Kim MC, Jeong YJ, et al. Pseudoxanthoma Elasticum-Like Disorder with Multiple Coagulation Factor Deficiency in a Patient with Crohn’s Disease. The Korean Journal of Medicine. 2015;89(4):474-7.
  2. Ghang B, Kwon O, Hong S, Lee CK, Yoo B, Kim YG. Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. Mod Rheumatol. 2017;27(3):405-10.
  3. Ghang B, Lee D, Hwang I, Lee CK, Yoo B, Kim YG. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents. Clin Exp Rheumatol. 2018;36(1):170.
  4. Ghang B, Kim JB, Jung SH, Chung CH, Lee JW, Song JM, et al. Surgical Outcomes in Behcet's Disease Patients With Severe Aortic Regurgitation. Ann Thorac Surg. 2019;107(4):1188-94.
  5. Kwon OC, Ghang B, Lee EJ, Hong S, Lee CK, Yoo B, et al. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus. Int J Rheum Dis. 2019;22(7):1305-11. (co-first author)
  6. Ghang B, Lee J, Chan Kwon O, Ahn SM, Oh JS, Hong S, et al. Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. Respir Med. 2019;155:43-8.
  7. Ghang B, Ahn SM, Kim J, Kim YG, Lee CK, Yoo B. Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial. Rheumatology (Oxford). 2020;59(6):1439-40.
  8. Bae S, Ghang B, Kim YJ, Lim JS, Yun SC, Kim YG, et al. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses. 2021;13(2). (co-first author)
  9. Ghang B, Nam SH, Lee J, Lim DH, Ahn SM, Oh JS, et al. Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients. Clin Rheumatol. 2021;40(6):2447-56.
  10. Choi S, Ghang B, Jeong S, Choi D, Lee JS, Park SM, et al. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting. Seminars in Arthritis and Rheumatism. 2021;51(4):685-91. (co-first author)
  11. Ghang B, Kim J. Colchicine as a Potential Treatment Choice for COVID-19 Patients in Developing Countries: COVID-19 and Colchicine. J Rheum Dis. 2022;29(1):56-7.
  12. Lee JS, Ghang B, Choi W, Hong S, Kim YG, Lee CK, et al. Expression of Inflammatory Markers in the Muscles of Patients with Idiopathic Inflammatory Myopathy According to the Presence of Interstitial Lung Disease. J Clin Med. 2022;11(11). (co-first author)
  13. Ghang BZ, Lee JS, Choi J, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 2022;8(2).
  14. Jeong S, Choi S, Park SM, Kim J, Ghang B, Lee EY. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Arthritis Res Ther. 2022;24(1):180. (co-corresponding author)
  15. Ghang B, Kim S, Kim J. Autoimmune rheumatic disease after SARS-CoV-2 vaccination. J Med Virol. 2022;94(12):5618-20. (co-first author)
  16. Kim HJ, Ghang B, Kim J, Ahn HS. Regional variations of cardiovascular risk in gout patients: a nationwide cohort study in Korea. J Rheum Dis. 2023;30(3):185-97
  17. Ghang B, Nam SH, Choi W, Kim HJ, Lee J, Lim DH, et al. Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies. Arthritis Res Ther. 2024;26(1):144.
  18. Choi J, Nam SH, Lee JS, Ahn SM, Hong S, Kim YG, et al. Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients. Clin Rheumatol. 2024;43(11):3379-87 (co-corresponding author)
  19. Ghang B, Park J, Lee JS, Lim JS, Kim H, Liew DFL, et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. 2025;107(3):521-9.
  20. Ghang B, Kim J, Kang T, Kim HJ. Ten-year cardiovascular risk changes and major adverse events in gout patients. Rheumatology. 2025